Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Health Industry
2,541 - 2,560 of 3,883 Results
-
-
Treating Cancer: Hope Vs. Hype
Dozens Of New Cancer Drugs Do Little To Improve Survival, Frustrating Patients
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
By Liz Szabo -
Georgia Legislative Panel Hears Concerns About Surprise Medical Billing
Insurers and care providers say efforts to fix how consumers are notified also raise concerns.
-
Repeal & Replace Watch
HHS Pick Price Made ‘Brazen’ Stock Trades While His Committee Was Under Scrutiny
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
By Marisa Taylor and Christina Jewett -
The Orphan Drug Machine
KHN Video: Warrior Luke
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
-
Trump’s Immigration Ban Fuels Fear For Young Doctors Whose Jobs May Be In Limbo
With announcements of placements in residencies expected in March, medical education groups and hospitals say they’re unsure how to proceed.
-
Women Fear Drug They Used To Halt Puberty Led To Health Problems
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
-
Repeal & Replace Watch
Democrats Say Cabinet Choice Tom Price ‘Misled’ The Public. Here’s What We Know.
Concerns over U.S. Rep. Tom Price’s answers about stock trades led Senate Democrats to boycott a committee vote that would have moved his nomination to the Senate floor.
-
Renewed Cleaning Efforts For Scopes Not Enough To Vanquish Bacteria
A new study, though small, finds extensive damage to commonly used medical scopes that could trap dangerous bacteria. That raises concerns about the potential for more outbreaks.
By Chad Terhune -
Getting Patients Hooked On An Opioid Overdose Antidote, Then Raising The Price
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
-
California Fines Kaiser Permanente $2.5 Million Over Missing Medicaid Data
The HMO blew two deadlines to supply information required by the state to monitor Medi-Cal managed care plans. Kaiser says it is “taking steps” to resolve the problem.
By Chad Terhune -
Repeal & Replace Watch
Trump’s HHS Choice: First A Letter To Medicare. Then A Campaign Contribution.
Rep. Tom Price, up for running HHS under President Trump, helped a company that became a top campaign donor, records show.
By Christina Jewett and Marisa Taylor -
People With Medical Debt Most Likely To Be Dunned By Collection Agencies
The Consumer Financial Protection Bureau reports in a new study that 59 percent of people contacted by a debt collector had outstanding medical bills.
-
Repeal & Replace Watch
Trump’s HHS Pick Favored Drugmakers, Device Makers And Doctors
Letters sent to Medicare from U.S. Rep. Tom Price, President Trump's pick to run HHS, supported physicians as well as drug or device makers, records show.
By Christina Jewett and Marisa Taylor -
Tackling Patients’ Social Problems Can Cut Health Costs
Intense, “high touch” care that focuses on housing as well as health care brings down medical costs for the most expensive patients. But it’s been hard to replicate successful programs.
By Sarah Varney -
Repeal & Replace Watch
Six U.S. Senators Confronting Trump’s HHS Cabinet Pick Own Health Care Stocks, Too
Donald Trump’s pick to run HHS has been under fire for trading health care stocks but at least six senators at his confirmation hearings also own such stocks.
-
21 Medicare Health Plans Warned To Fix Provider Directory Errors
Federal officials release names of insurers who ranked poorly in a recent review of their online directories’ accuracy.
By Phil Galewitz and Susan Jaffe -
The Orphan Drug Machine
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Timeline: The Orphan Drug Act
Follow the twists and turns of the orphan drug industry over the past three decades.